Evidence map›Paper›PMID 40992541›Full record

ArticleContemporary clinical trials2025

Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER

Dana E Rollison, Melany A Garcia, Rossybelle P Amorrortu, Yayi Zhao, Brian Mittman, Kea Turner, Kedar Kirtane, Hatem Soliman, Margaret M Byrne, Cathy Meade and 8 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Dana E RollisonDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA; Office of Health Data Services, Moffitt Cancer Center, Tampa, FL, USA.
Melany A GarciaDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Rossybelle P AmorrortuDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Yayi ZhaoDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Brian MittmanDepartment of Research and Evaluation, Kaiser Permanente, Los Angeles, CA, USA.
Kea TurnerDivision of Health Systems, Policy, and Innovation, University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, NC, USA.
Kedar KirtaneDepartment of Head and Neck Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Hatem SolimanDepartment of Breast Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Margaret M ByrneDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Cathy MeadeDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Clement K GwedeDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Steven EschrichDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Jun YinDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Nathanael B StanleyOffice of Community Outreach and Engagement, Moffitt Cancer Center, Tampa, FL, USA.
Lindsay FuzzellDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Delilah HernandezOffice of Community Outreach and Engagement, Moffitt Cancer Center, Tampa, FL, USA; Non-Therapeutics Research Office, Moffitt Cancer Center, Tampa, FL, USA.
Elliott-Tapia-KwanOffice of Community Outreach and Engagement, Moffitt Cancer Center, Tampa, FL, USA; Non-Therapeutics Research Office, Moffitt Cancer Center, Tampa, FL, USA.
Susan T VadaparampilDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA; Office of Community Outreach and Engagement, Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Susan.Vadaparampil@moffitt.org.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS)U01CA274971 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SUSAN T VADAPARAMPIL · 2022 to 2026
$3.9M
NCI NIH HHS P30 CA076292NCI NIH HHS U01 CA274971
6 · The paper itself

Abstract

introductionNon-Hispanic (NH) Black/African American (AA) and Hispanic cancer patients are underrepresented in cancer clinical trials (CCTs) due to patient, physician, and system-level barriers. Therefore, multi-level approaches are critical to address barriers to CCT participation. Presented here are the study design and baseline characteristics of ACT WONDER

methodsACT WONDER

resultsApproximately 16.5 % and 35.8 % of the intervention priority zones are NH Black/AA or Hispanic, respectively. There are no statistically significant differences between groups in total population size (paired t-test p-value = 0.63), proportions of NH Black/AA (p = 0.13) and Hispanic populations (p = 0.17), or distance in miles from MCC (p = 0.64). The estimated number of cancer cases and CCT enrollment rates at baseline are also similar between groups.

conclusionIf shown to be effective in increasing referral and enrollment of NH Black/AA and Hispanic cancer patients to CCTs, ACT WONDER

Indexed as

Black or African AmericanClinical Trials as TopicHispanic or LatinoNeoplasmsPatient SelectionReferral and ConsultationFemaleHealthcare DisparitiesHealth Services AccessibilityHumansMaleMiddle AgedMinority GroupsResearch DesignCancer clinical trialsGeospatial analysisHealth disparitiesMulti-level interventionsStudy designs

Identifiers

PMID40992541
PMCPMC12707367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.